FindTrial
Sign In

Conditioning chemotherapy

DRUG6 trials

Sponsors

National Cancer Institute (NCI), University of Wisconsin, Madison, Memorial Sloan Kettering Cancer Center

Conditions

Acute LeukemiaAcute Lymphoblastic Leukemia (ALL)Acute Myelogenous Leukemia (AML)Acute Myeloid LeukemiaChronic Myelogenous Leukemia (CML)Hodgkin's LymphomaLeukemiaMultiple Myeloma

Phase 1

Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System
CompletedNCT00520130
National Cancer Institute (NCI)Acute Leukemia, Hodgkin's Lymphoma, Multiple Myeloma +2
Start: 2007-10-30End: 2018-12-31Updated: 2019-03-05
Haploidentical Transplant With NK Cell Infusion for Pediatric Acute Leukemia and Solid Tumors
TerminatedNCT00582816
University of Wisconsin, MadisonLeukemia, Solid Tumors
Start: 2008-08-31End: 2015-08-31Updated: 2019-12-09
Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
CompletedNCT02356159
National Cancer Institute (NCI)Acute Leukemia, Hodgkin's Lymphoma, Multiple Myeloma +2
Start: 2015-09-24End: 2025-03-25Updated: 2025-09-30
A Study of Radiation Therapy Before CAR T Cell Therapy for People With B Cell Lymphoma
Active, not recruitingNCT05574114
Memorial Sloan Kettering Cancer CenterNon-Hodgkin Lymphoma, Non-Hodgkin's Lymphoma Refractory, Non-Hodgkin's Lymphoma, Relapsed
Start: 2022-10-05End: 2026-10-31Updated: 2025-11-04
A Study of ADCLEC.syn1 in People With Acute Myeloid Leukemia
RecruitingNCT05748197
Memorial Sloan Kettering Cancer CenterAcute Myeloid Leukemia
Start: 2024-04-18End: 2028-04-18Target: 40Updated: 2026-03-10

Phase 2

Cord Blood Transplant in Adults With Blood Cancers
RecruitingNCT05884333
Memorial Sloan Kettering Cancer CenterAcute Lymphoblastic Leukemia (ALL), Acute Myelogenous Leukemia (AML), Chronic Myelogenous Leukemia (CML) +3
Start: 2023-05-22End: 2028-05-22Target: 54Updated: 2025-09-08

Related Papers

Impact of fludarabine exposure on overall survival in patients receiving fludarabine/cyclophosphamide reduced intensity conditioning hematopoietic cell transplantation for hematologic malignancies
Blood2025-11-03
Phase 1/2 study of high-dose palifermin for GVHD prophylaxis in patients undergoing HLA-matched unrelated donor HCT
Blood2025-05-071 citations
A Proof-of-Principle of Split-Course Bridging Radiotherapy (SC-BRT) Prior to CAR T-Cell Therapies for Relapsed or Refractory B-Cell Lymphomas: A Phase 1a Pilot Cohort
Blood2024-11-051 citations
High-dose alemtuzumab and cyclosporine vs tacrolimus, methotrexate, and sirolimus for chronic graft-versus-host disease prevention
Blood Advances2024-04-269 citations
Preconditioning Single High-Dose Palifermin Alters the Posttransplant Inflammatory Cytokine Profile
Blood2023-11-02
S104: DIFFERENTIAL TARGET PROFILES AND EFFICACY OF ADCLEC.SYN1 AND CD33-CARS IN HUMANIZED AML MODELS
HemaSphere2023-08-012 citations
A PHASE I STUDY OF SPLIT‐COURSE BRIDGING RADIOTHERAPY (SC‐BRT) PRIOR TO COMMERCIAL CD19 CAR T‐CELL THERAPIES FOR PATIENTS WITH RELAPSED OR REFRACTORY B‐CELL LYMPHOMAS
Hematological Oncology2023-06-011 citations
A Phase 1 Single Dose Escalation Study of Palifermin Administered Pre-Transplant Conditioning in Subjects Undergoing Matched Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation
Blood2020-11-052 citations
Salivary Zymogen Granule Protein 16B Drops at Onset of Chronic Graft-Versus-Host Disease: A Possible Salivary Biomarker for Oral Chronic Graft-Versus-Host Disease
Biology of Blood and Marrow Transplantation2019-01-31
Human Th17 activity profile in oral chronic Graft-versus-Host Disease
The Journal of Immunology2017-05-01
Th17 Recruitment and Interferon Pathway Activation in Oral Chronic Graft-Versus-Host Disease Tissues
Biology of Blood and Marrow Transplantation2016-02-18
Upregulation of Interferon-Inducible and Damage Response Receptors in Chronic Graft-Versus-Host Disease
Blood2015-12-033 citations
Alemtuzumab-Cyclosporine Versus Tacrolimus-Methotrexate-Sirolimus for Graft-Versus-Host Disease Prophylaxis in Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation from Unrelated Donors: Final Results of a Randomized Trial
Blood2015-12-032 citations